DEPARTMENT NAME
Department of Biopharmacy

CONTACT DETAILS FOR HEAD OF DEPARTMENT
Prof. Daria Orszulak-Michalak (PhD)
daria.orszulak-michalak@umed.lodz.pl
+48 42 677 91 21

Department of Biopharmacy
ul. Muszyńskiego 1
90-151 Lodz, Poland

TEAM MEMBERS
Prof. Daria Orszulak-Michalak (PhD)
Dr Magdalena Jasińska-Stroschein (PhD)
Dr Urszula Kurczewska (PhD)
Dr Aneta Mamos (MD, PhD)
Dr Piotr Szcześniak (PhD)
Mgr Magdalena Bulska (MPharm)
Mgr Joanna Orłowska (MPharm)

SHORT DESCRIPTION OF RESEARCH ACTIVITY

1. Identification of diagnostic markers involved in the pathogenesis of selected lifestyle diseases (e.g.,cardiovascular, gastrointestinal disorders).
2. Evaluation of drug-drug interactions for cardiovascular therapies. Therapeutic activity of novel agents in pulmonary hypertension. Experimental studies on animal models.
3. Biopharmaceutical assessment of medical products and devices (in vitro, in vivo)

DEPARTMENTAL ACHIEVEMENTS: PROJECTS AND PAPERS

1. Orłowska J et al. The use of biodegradable polymers in design of cellular scaffolds. Postępy Hig Med Dosw(Online). 2015, 5
2. Mokrowiecka A et al. Serum adiponectin, resistin, leptin concentration and central adiposity parameters inBarrett’s esophagus patients with and without intestinal metaplasia in comparison to healthy controls and patients with GERD. Hepatogastroenterology. 2012, 59
3. Jasińska-Stroschein M et al. HMG-COA reductase inhibitors: An opportunity for the improvement of imatinibsafety. An experimental study in rat pulmonary hypertension. Pharmacol Rep. 2015, 67
4. Jasińska-Stroschein M et al. Rosuvastatin intensifies the beneficial effects of Rho-kinase inhibitor in reversal ofmonocrotaline-induced pulmonary hypertension. Arch Med Sci. 2016, 12
5. Jasińska-Stroschein M et al. Statistical Considerations Concerning Dissimilar Regulatory Requirements for Dissolution Similarity Assessment. The Example of Immediate-Release Dosage Forms. J Pharm Sci. 2017, 106